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Abstract
Cholesterol accumulates in prostate lesions and has been linked to prostate cancer (PCa) incidence 
and progression. However, how accumulated cholesterol contributes to PCa development and 
progression is not completely understood. Cholesterol sulfate (CS), the primary sulfonation 
product of cholesterol sulfotransferase (SULT2B1b), accumulates in human prostate 
adenocarcinoma and precancerous prostatic intraepithelial neoplasia (PIN) lesions compared to 
normal regions of the same tissue sample. Given the enhanced accumulation of CS in these 
lesions, it was hypothesized that SULT2B1b-mediated production of CS provides a growth 
advantage to these cells. To address this, PCa cells with RNAi-mediated knockdown (KD) of 
SULT2B1b were used to assess the impact on cell growth and survival. SULT2B1b is expressed 
and functional in a variety of prostate cells and the data demonstrate that SULT2B1b KD, in 
LNCaP and other androgen-responsive (VCaP and C4-2) cells, results in decreased cell growth/
viability and induces cell death. SULT2B1b KD also decreases androgen receptor (AR) activity 
and expression at mRNA and protein levels. While AR overexpression has no impact on 
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SULT2B1b KD-mediated cell death, addition of exogenous androgen is able to partially rescue the 
growth inhibition induced by SULT2B1b KD in LNCaP cells. These results suggest that 
SULT2B1b positively regulates the AR either through alterations in ligand availability or by 
interaction with critical co-regulators that influence AR activity.
Implications—These findings provide evidence that SULT2B1b is a novel regulator of AR 
activity and cell growth in prostate cancer and should be further investigated for therapeutic 
potential.
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INTRODUCTION
Prostate cancer (PCa) is the second leading cause of non-cutaneous cancer death among 
males in the United States with 180,890 new cases and 26,120 deaths estimated in 2016(1). 
Current treatments for organ-confined disease, including prostatectomy and radiation, have 
proven to be successful. Unfortunately, the initial treatment for metastatic disease, androgen-
deprivation therapy (ADT), is palliative, providing only approximately 11 months of failure-
free survival(2). Progression leads to the development of castration resistant prostate cancer 
(CRPC) for which second generation ADT is available but the response is also short-
lived(3,4). Further investigation into the biology of PCa and identification of novel 
regulators of cellular growth and/or androgen receptor (AR) activity is required for alternate, 
more curative therapeutic options for men with advanced PCa.
Cholesterol metabolism dysregulation has been investigated in PCa for many years leading 
to a better understanding of cholesterol’s contribution to disease progression. Through 
modulation of intracellular signaling and pro-survival pathways, cholesterol metabolism is 
believed to play a major role in PCa development and progression to the castration non-
responsive state, but the mechanisms involved remain elusive(5–9). A number of modified 
forms of cholesterol are found within cells, namely hydroxysterols, cholesterol esters, and 
cholesterol sulfate (CS). Previously, desorption electrospray ionization mass spectrometry 
(DESI-MS) was used to identify unique lipid profiles in human prostate tissue specimens, 
where CS was observed to be elevated in prostatic intraepithelial neoplasia (PIN) and 
adenocarcinoma lesions compared to normal tissues(10). This suggested that the enzyme(s) 
responsible for converting cholesterol to CS were not simply expressed, but functional in 
these tissues.
Cytosolic sulfotransferases (SULTs) are a class of enzymes that catalyze the sulfonation of 
various hydroxysteroid substrates. SULT members within this class each have preferential 
affinity for various substrates. For example, SULT2A1 is expressed in the liver and adrenal 
gland where it utilizes dehydroepiandrosterone (DHEA) as a substrate to produce and 
secrete the abundant circulating hormone precursor, DHEA-sulfate; SULT2A1 has been 
studied in PCa as a result of this function(11). SULT2B1 has two isoforms, SULT2B1a and 
SULT2B1b, which differ only by 15 amino acids at the N-terminus due to alternate 
transcriptional start sites of the same gene. SULT2B1a and SULT2B1b each have different 
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substrate affinities.(12) SULT2B1b, the “cholesterol sulfotransferase,” is expressed in a 
variety of tissues, including the prostate, placenta, and skin, but it is unclear whether 
SULT2B1a is expressed at the protein level in any human tissues(12–14). SULT2B1b-
catalyzed production of cholesterol sulfate (CS) is critical for skin barrier layer formation 
and proper membrane function of a variety of cell types(13,15). SULT2B1b also is known to 
influence cell metabolism through regulation of the Liver X Receptor (LXR), a global 
regulator of cholesterol homeostasis(16).
Studies have shown a potential role of SULT2B1b in the growth and progression of cancer 
cells(17–20). SULT2B1b was studied in PCa in androgen-free conditions supplemented with 
DHEA(19,21). However, SULT2B1b has not been previously evaluated in androgen-replete 
conditions that mimic normal biology and PCa progression, consistent with the conditions in 
which CS accumulation was observed(10). Here, we investigate the impact of SULT2B1b in 
PCa cells in the presence of androgen with the hypothesis that enzymatic activity of 
SULT2B1b supports cell growth and contributes to progression of the disease through 
modulation of LXR and AR activity. Studies reported herein verify that SULT2B1b is an 
important metabolic enzyme in multiple PCa cell lines by demonstrating that SULT2B1b 
knockdown (KD) induces caspase-3 activation and cell death. Additionally, data show that 
SULT2B1b activity positively correlates with AR activity in PCa cells. This positive 
regulation of AR by SULT2B1b appears to be LXR-independent and may be due to 
alterations in AR expression levels or ligand availability, since replenishing testosterone 
partially overcomes the growth-inhibitory effects of SULT2B1b KD. These studies support a 
novel mechanism of AR regulation in PCa cells. Thus, therapeutic targeting of SULT2B1b 
may be a novel approach to inhibiting AR activity in PCa.
MATERIALS AND METHODS
Human Prostate Tissue Source and Immunohistochemistry
A random selection of four unpaired and four paired frozen, human prostate tissue samples 
were obtained from the Indiana University Simon Cancer Center Tissue Bank. All tissues 
were handled in accordance with the Indiana University institutional review board and 
prepared as previously described(10). Frozen sections were prepared on slides and subjected 
to hematoxylin and eosin (H&E) staining and pathological evaluation.
For SULT2B1b immunohistochemistry (IHC), slides containing frozen tissue specimens 
were rinsed with ddH20 and subjected to the following treatments: 3% hydrogen peroxide, 
protein block solution (#X0909, Dako), 1:500 anti-SULT2B1 primary antibody (ab88085, 
Abcam), peroxidase-linked polymeric anti-mouse antibody (K4006, Dako), and 3,3’-
diaminobenzidine (Dako). Samples were washed between each step and Gills II hematoxylin 
was used as a counterstain.
Desorption Electrospray Ionization (DESI) Mass Spectrometry
A laboratory-built DESI ion source, similar to the commercial 2D source from Prosolia, Inc. 
(Indianapolis, IN, USA) was coupled to a linear ion trap mass spectrometer (LTQ) controlled 
by XCalibur 2.0 software (ThermoFisher Scientific, Waltham, MA) and used in all 
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experiments. The negative ionization mode was used with the automatic gain control (AGC) 
inactivated. Tissues were analyzed as previously described(10). For cell lines, the spray 
solvent used for DESI-MS was dimethylformamide (DMF)-acetonitrile (ACN) at a 1:1 ratio 
in volume; both solvents were purchased from Mallinckrodt Baker Inc.(Phillipsburg, NJ) 
and infused over the cell line material at 1.0 µL/min flow rate through the instrument syringe 
pump. The DESI source parameters are indicated in Supplemental Materials and Methods. 
Each cell line was analyzed by manual movement of a 2D moving stage where the slide was 
held in a fixed position. Full scan mass spectra were acquired in negative ion mode in the 
mass range m/z 200–1000.
Cell Lines
LNCaP, VCaP, RWPE-1, PC-3, and DU 145 were purchased from the American Tissue 
Culture Collection (ATCC; Manassas, VA) and maintained in media conditions identical to 
those recommended by ATCC. C4-2 cells were a generous gift from MD Anderson 
(Houston, TX) and were maintained in T-medium (Invitrogen) supplemented with 10% FBS 
and 1% streptomycin/penicillin. Cell lines were verified using cell line authentication testing 
from DDC Medical (Fairfield, OH) through the generous support of the Prostate Cancer 
Foundation and results are shown in Supplemental Table 1. All experiments were completed 
within 20 passages of acquisition from ATCC.
RNA interference (RNAi)
For siRNA KD, SULT2B1 (HSC.RNAI.N004605.12.2), NR1H2 (LXRβ, 
HSC.RNAI.N007121.12.2), and NR1H3 (LXRα, HSC.RNAI.N005693.12.2) predesigned 
DsiRNA duplexes were purchased from IDT. Non-targeting siRNA was purchased as a 
control (Dharmacon Scientific). Transfection using Lipofectamine RNAiMax (Invitrogen) 
was completed for all siRNA transfections according to the manufacturer’s instructions. For 
double siRNA KD, combinations of the same amount of siRNA were incubated with double 
the recommended transfection reagent prior to adding to cells in culture. “Controlx2” 
indicates twice the amount of non-targeting siRNA and double RNAiMax compared to 
“Control” samples. For shRNA KD in LNCaP cells, SULT2B1 and control sequences 5’-
CCTCTATCATTACTCCAAGAT-3’ (LNKD) and 5’-CCATTAACTCTTTCCCGAAAT-3’ 
(LNCon), respectively, were inserted into the pLNKO.1 Tet-ON vector (Addgene) and 
transfected using FuGene HD (Promega). Finally, SULT2B1 shRNA and copGFP Control 
Lentiviral particles (Santa Cruz Biotechnology, Inc. sc-44399-V and sc-108084, 
respectively) were transduced in LNCaP cells using Polybrene ® (Santa Cruz sc-134220). 
The appropriate method of SULT2B1b KD is indicated in figure legends.
RNA isolation, cDNA amplification, and qRT-PCR
Total RNA was isolated using the E.Z.N.A. Total RNA Kit I (Omega Biotek) according to 
the manufacturer’s instructions. cDNA was prepared by mixing 2–4 µg total RNA, 250µM 
dNTPs (Amresco), 0.5 µM each of random hexamer and oligo(dT)15 primers (Promega), and 
200 units M-MLV reverse transcriptase with included reaction buffer(NEB). qRT-PCR was 
conducted using PerfeCTa® FastMix® II (Quanta Biosciences) according to the 
manufacturer’s instructions. PrimeTime ® qRT-PCR gene probes (IDT) used for these 
studies include: ABCG1 (Hs.PT.56a.20848083.g), AR (Hs.PT.56a.38770693), KLK3 which 
Vickman et al. Page 4
Mol Cancer Res. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
will be identified herein as “PSA” (Hs.PT.56a.38546086.g), NR1H2 (Hs.PT.56a.
45297581.g), NR1H3 (Hs.PT.56a.40638751.g), and SULT2B1 (Hs.PT.56a.25562421.g). 
“Relative mRNA expression” levels were calculated and normalized to 18s rRNA 
(Cat#4308329, Applied Biosystems), as described previously.(22)
Antibodies and Reagents
The following antibodies were used for western blots: anti-β-actin clone 8H10D10 ab#3700, 
anti PARP ab#9542 (Cell Signaling Technologies); anti-SULT2B1 ab88085 (Abcam); anti-
AR clone 441, anti-β-tubulin T0198, and goat anti-mouse IgG-HRP (Santa-Cruz); anti-
human PSA A0562 (Dako); and goat anti-rabbit IgG-HRP (Vector Laboratories). The 
approximate molecular weight of each protein is indicated with blots in relevant figures.
Caspase-3 activity was measured after 72 hours of siRNA transfection using the Caspase-
Glo® 3/7 assay (Promega, Madison, WI) and analyzed using a Luminoskan Ascent 
microplate luminometer (Thermo Scientific) according to the manufacturer’s instructions. 
CellTiter 96® AQueous One Solution Reagent (Promega) was used for MTS cell proliferation 
assays, and relative absorbance was quantified by a Multiskan FC plate reader 
(ThermoScientific). For relevant assays, 10µM pan-caspase inhibitor Z-VAD-FMK 
(Promega) and/or 20µM Necrostatin-1 (Sigma) was added to cells at the time of siRNA 
transfection. Synthetic androgen, R1881 (Sigma), was used at the indicated concentrations.
Production of DU 145-SULT2B1b and LNCaP-SULT2B1b cells
To produce cell lines with tetracycline-inducible expression of SULT2B1b, consecutive 
lentiviral transductions were performed. DU 145 or LNCaP cells were transduced with 
lentivirus produced from the Lenti-X™ Tet-On® Advanced Inducible Expression System 
(Clontech) and then from the pLVX-Tight-Puro lentiviral vector (Clontech) containing 
human SULT2B1b cDNA. The SULT2B1b cDNA transcript was obtained from Dr. Charles 
Falany (University of Alabama). Stable selection of both transductions resulted in DU 145-
SULT2B1b or LNCaP-SULT2B1b cells. Additional information is available in Supplemental 
Materials and Methods.
Soft-agar assay
LNCaP cells were transfected with shRNA plasmids in 60-mm dishes for 24 hours and 
harvested. Soft agar plates were prepared as described in Supplemental Materials and 
Methods. Each layer received 1 µg/mL doxycycline for induction of Tet-ON shRNA 
plasmids. Plates were incubated for 7 days and then cell colonies were counted.
Flow Cytometry: Cell cycle analysis and Annexin-V staining
Treated cells were harvested and then washed twice with PBS, fixed in 75% ethanol, and 
stored at −20°C for up to 7 days. To prepare for flow cytometry, cells were stained with PI 
(Biolegend #421301) and, in relevant assays, Annexin-V (Biolegend #640920) according to 
the manufacturer’s instructions. Staining buffer details are indicated in Supplemental 
Materials and Methods. Cells were stained at room temperature before analysis on 
FACSCanto II (BD Biosciences, San Jose, CA). Further analysis of DNA content was 
completed via FlowJo software version 9 (TreeStar Inc., Ashland, OR).
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Luciferase assays and reporter constructs
AR activity was measured by luciferase assay, as described previously(23). SULT2B1b or 
AR overexpression was conducted transiently under a CMV promoter. Briefly, LNCaP cells 
were transfected with shRNA/siRNA, pRL-TK (Promega), and a construct controlled by the 
AR-responsive portion of the PSA promoter driving firefly luciferase(23). Assays with 
shRNA KD constructs were transfected simultaneously with luciferase plasmids using 
Fugene HD (Promega). Assays with siRNA KD were first transfected with luciferase 
plasmids using Fugene HD for 8–16 hours and then media was changed for consecutive 
transfection with siRNA as described above. After 24 hours RNAi transfection, 1nM R1881 
(Sigma) or ethanol control was added to respective wells and incubated for an additional 24 
hours. Then, cell lysates were tested for Firefly and Renilla luciferase activity using the Dual 
Luciferase Reporter Assay kit (Promega)(24) and relative luciferase activity (RLU=Firefly/
Renilla) of the AR is shown as mean +/− SEM from at least three independent experiments 
performed in triplicate.
LXR activity was determined by transfecting LNCaP cells with LXR-RE or Negative 
Control plasmids (Qiagen CCS-0041L) along with Control or SULT2B1b siRNA. After 
indicated time of transfection, cells were lysed and analyzed as above. Data was interpreted 
by determining RLU and then further normalizing samples containing the LXR-RE reporter 
to samples transfected with the Negative Control reporter.
Statistical analysis
Data were represented as the mean ± standard error of the mean. Statistical analysis was 
performed using the unpaired two-tailed student’s t test or two-way ANOVA and analyzed 
by GraphPad Prism 5 (La Jolla, CA) or SAS Enterprise (Cary, NC).
RESULTS
Cholesterol sulfate accumulation correlates with SULT2B1b expression in PCa cells and 
human tissue specimens
We previously demonstrated that CS accumulation occurs within PIN and PCa tissues 
compared to normal prostate tissues(10). As an extension of the previous work, a small 
subset of samples (12 samples ranging from normal to high-grade carcinoma obtained from 
8 different patients) was randomly selected from the Indiana University Simon Cancer 
Center Tissue Bank for comparison of the co-localization of SULT2B1b staining by 
immunohistochemistry (IHC) and areas of CS accumulation by DESI-MS. These studies 
showed that areas with CS detection were limited to regions of positive SULT2B1b 
expression (Figure 1A, Supplemental Figure 1). To study the role of SULT2B1b in vitro, 
human prostatic epithelial cell lines were analyzed for SULT2B1b expression and activity. 
Androgen responsive cell lines LNCaP, VCaP, RWPE-1, and the castration non-responsive 
line C4-2 generally express higher levels of SULT2B1b than AR- cell lines, such as PC-3 
and DU 145 cells (Figure 1B–C). In general, SULT2B1b expression in these cell lines 
corresponds to detection of CS, indicating functional activity of SULT2B1b (Figure 1D). 
However, it is noteworthy that SULT2B1b can be expressed but not active, as in PC-3 cells 
(Figure 1B–D). To demonstrate that CS production was the result of SULT2B1b activity 
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specifically, expression of SULT2B1b was induced in cells that normally express a minimal 
level of SULT2B1b. A stable, doxycycline-inducible DU 145-SULT2B1b cell line was 
developed to overexpress SULT2B1b. Induction of SULT2B1b expression by doxycycline 
resulted in a striking increase in the relative abundance of CS (Figure 1E–F). Similarly, 
inducing SULT2B1b overexpression in doxycycline-inducible LNCaP-SULT2B1b cells 
resulted in an increase in the relative abundance of CS (Supplemental Figure 2A). 
Conversely, SULT2B1b knockdown (KD) in LNCaP cells decreased the relative abundance 
of CS (Supplemental Figure 2B). While not quantitative, these DESI-MS observations 
provide strong correlative evidence that SULT2B1b activity is responsible for the 
accumulated CS in PCa.
Targeted knockdown of SULT2B1b impairs growth/viability of PCa cells
In order to determine if SULT2B1b impacts PCa through production of its product, CS, 
exogenous CS was added to LNCaP and observed for alterations in phenotype and growth 
characteristics. Notably, no overt phenotypic changes in growth or cell death were observed 
(data not shown). Similarly, overexpression of SULT2B1b in LNCaP cells did not enhance 
growth (data not shown). Thus, RNAi-mediated KD of SULT2B1b was performed to better 
understand the function of this enzyme in PCa cells. SULT2B1b KD resulted in a decrease 
in growth/viability of LNCaP, VCaP, C4-2, and RWPE-1 cells as well as decreased soft-agar 
colony formation in LNCaP cells (Figure 2, Supplemental Figure 3). Importantly, a 
significant decrease in cell growth/viability was observed using multiple SULT2B1b RNAi 
sequences in LNCaP cells (Figure 2A,D,E, Supplemental Figure 4A).
SULT2B1b knockdown induces cell death in PCa cells
Further investigations showed SULT2B1b KD increased the percentage of sub-G1 nuclei by 
cell cycle analysis and significantly increased caspase-3 activity and PARP cleavage in both 
LNCaP and VCaP cells (Figure 3A–C). Increased sub-G1 nuclei percentages and caspase-3 
activation was also observed in C4-2 cells with SULT2B1b KD (Supplemental Figure 5). 
Furthermore, LNCaP cells with SULT2B1b KD analyzed by flow cytometry showed an 
increased percentage of Annexin-V+/propidium iodide (PI)- cells compared to control KD 
cells (Figure 3D–E).
To determine whether caspase activation was an essential aspect of the induced cell death, 
abrogation of apoptosis by the addition of a pan-caspase inhibitor, Z-vad-fmk (Z-vad), was 
tested in SULT2B1b KD LNCaP cells. Results indicated that Z-vad successfully blocked 
caspase-3 activation and abrogated the enhancement of Annexin-V+/PI- cells after 
SULT2B1b KD, but LNCaP cell viability and, ultimately, cell death was not altered (Figure 
4A–C). While the complete mechanism(s) of cell death are not understood, it is possible that 
after pan-caspase inhibition SULT2B1b KD cells activated alternative cell death pathways. 
Additional studies completed in SULT2B1b KD cells with co-treatment of Z-vad and an 
additional inhibitor of RIP1 kinase, Necrostatin-1, yielded a greater proportion of viable 
cells compared to Z-vad treatment alone (Figure 4D). It may be of note that although LNCaP 
cells with SULT2B1b KD respond to Necrostatin-1 treatment with concurrent pan-caspase 
inhibition, our studies investigating reactive oxygen species production and AnnexinV-/PI+ 
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cells did not show that RIP1 kinase-dependent death pathways (i.e. during necroptosis(25)) 
are directly induced by SULT2B1b KD (data not shown).
SULT2B1b activity modulates AR activity in PCa cells
PCa cells rely on AR activity for growth and stimulation and previous studies have 
demonstrated that cholesterol can be used as a precursor for androgen synthesis(6,26). Thus, 
the impact of SULT2B1b modulation on AR expression and activity was evaluated. The data 
show that SULT2B1b KD by various methods in LNCaP cells decreases AR expression as 
well as AR activity measured by both prostate specific antigen (PSA) expression and 
transcription of the AR-response element (AR-RE) within the PSA promotor (Figure 5, 
Supplemental Figure 4B–C).
Further investigation showed that the decreased expression of the AR mediated by 
SULT2B1b KD was not the cause of decreased cell growth, since transient overexpression of 
the AR in LNCaP cells with SULT2B1b KD showed no increase in cell growth over LNCaP 
cells with SULT2B1b KD alone (Figure 6A–C). Endpoint analysis of a growth assay in 
LNCaP cells shows that replenishing the culture medium with synthetic androgen, R1881, 
partially, yet significantly, rescued the reduced cell growth in SULT2B1b KD LNCaP cells 
back to Control KD levels (Figure 6D).
SULT2B1b regulates the AR independently of LXR
Transient overexpression of the human SULT2B1b cDNA was performed to address whether 
or not SULT2B1b activity regulates LXR activity in PCa cells(27). LNCaP cells with 
SULT2B1b overexpression (hSULT2B1b vector) showed a significant decrease in LXR 
activity and a trend of decreased transcription of downstream target gene, ATP-binding 
cassette (ABC)-G1 (Figure 7A–C).
Additionally, since LXR activation has been shown to decrease AR activity(28), the question 
of whether activation of LXR in SULT2B1b KD cells causes decreased AR transcription 
was addressed. Double siRNA KD of SULT2B1b and LXRβ was performed followed by the 
assessment of AR activity through PSA expression (Figure 7D–F). LXRα was excluded 
because LXR activity in LNCaP cells was demonstrated to be due to transcriptional 
activation of LXRβ (Figure 7D, Supplemental Figure 6). Double KD of SULT2B1b/LXRβ 
did not impact the siRNA KD efficiency compared to SULT2B1b or LXRβ KD alone 
(Figure 7E). Regardless of whether or not LXR was present/active, SULT2B1b KD was still 
able to inhibit AR activity, as shown by a significant reduction in PSA expression (Figure 
7F).
DISCUSSION
We previously reported that CS accumulates in precancerous and cancerous human prostate 
specimens(10). To date, the role of CS in the prostate or the impact of accumulated CS 
within prostatic cells is not known. Data in this study utilized DESI-MS technology to show 
CS accumulation is the result of increased SULT2B1b activity, rather than simply 
expression, within prostate cells (Figure 1, Supplemental Figure 1). Detection of 
accumulated CS at the macroscopic level reveals either enhanced activity of SULT2B1b or 
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an inability of the tissue to secrete or utilize this product. Nonetheless, the use of DESI-MS 
in these studies allowed the validation that manipulation of SULT2B1b in cell lines led to 
functional alterations (Figure 1E–F, Supplemental Figure 2).
Mechanisms of SULT2B1b function other than sulfonation (15,16) have not been well 
described. In contrast to our findings, two groups independently reported that SULT2B1b 
KD promotes LNCaP cell growth while maintained in androgen-depleted conditions with 
DHEA supplementation(19,21). Although we do not fully understand the reason(s) for this 
discrepancy, culture medium conditions in growth assays may play a role. While their data 
support the logical hypothesis that SULT2B1b-mediated sulfonation causes “inactivation” of 
steroid precursors (i.e. DHEA) leading to decreased AR-dependent proliferative signaling, 
data herein directly show that SULT2B1b activity is positively correlated to AR activity, 
which implies an alternative mechanism of AR regulation is occurring. While our studies in 
cell lines support our previous findings that CS accumulates in precancerous and cancerous 
prostate tissues compared to normal counterparts, we also found that a single benign cell 
line, RWPE-1, has robust SULT2B1b expression and activity, which likely reflects the 
heterogeneity of SULT2B1b expression/activity within prostate tissue as has been reported 
by others(19). In contrast to the findings of Seo et al.(19), recent evidence in cancer cells 
suggest SULT2B1b plays a role in cancer growth/aggressiveness. It has been demonstrated 
that SULT2B1b activity increases gastric cancer angiogenesis and tumor volume, 
SULT2B1b activity promotes hepatocellular carcinoma cell growth in vitro and in vivo, and 
SULT2B1b expression correlates with poor prognosis and promotes tumor cell growth in 
colorectal cancer patients.(17,18,20) In fact, the Human Protein Atlas database (http://
www.proteinatlas.org/ENSG00000088002-SULT2B1/cancer) of tissue samples supports 
elevated expression levels of SULT2B1b in PCa compared to normal tissue. As a result of 
the controversial role of SULT2B1b activity, additional studies in PCa are required to fully 
understand its function.
We hypothesize that SULT2B1b continues to be essential for PCa cell growth throughout 
progression of the disease, as our data demonstrate that SULT2B1b KD induces cell death in 
both androgen-dependent and CRPC cell lines (Figures 2–4, Supplemental Figure 5). 
However, it remains to be determined whether SULT2B1b activity influences the 
progression of androgen-dependent PCa cells toward a castration non-responsive state. 
Notably, our past investigation of human clinical PCa specimens did not find any correlation 
between CS accumulation and PCa stage/grade(10).
Cell death induced by SULT2B1b KD includes caspase-3 activation, but pan-caspase 
inhibition does not reduce cell death overall as it appears other death mechanisms, such as 
RIP1 kinase-related pathways, can become activated (Figure 4B,D). All of these data 
suggest that KD of SULT2B1b in PCa cells alters cellular metabolism that results in cell 
death, perhaps by a variety of pathways. Although an exact mechanism of how this 
cholesterol sulfotransferase could be linked to cell viability was not defined here, the data 
supporting SULT2B1b-mediated modulation of AR activity likely plays a role.
SULT2B1b activity has been shown to decrease activity of the LXR through inactivation of 
endogenous oxysterol ligands and we showed similar results in PCa cells (Figure 7A–C)
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(16). Additionally, chemical activation of the LXR with agonist TO901317 has been shown 
to induce cell death in LNCaP cells grown in serum-free medium(21). We observed that 
SULT2B1b KD-induced activation of the LXR was minimal compared to direct activation 
by TO901317 (data not shown), suggesting that SULT2B1b KD in complete medium 
conditions may endogenously regulate LXR in addition to alternative pathways that 
culminate in a cell death phenotype.
A possible alternative would be that SULT2B1b KD induces cell death through its impact on 
AR expression and activity (Figure 5, Supplemental Figure 4B–C).(29) However, this may 
not be due to reduced AR expression levels since overexpression of the AR with SULT2B1b 
KD does not rescue the cell death phenotype (Figure 6A–C). Additionally, even though 
some of the included cell lines do express AR variants, we do not suspect that SULT2B1b 
function relies completely on variant forms since SULT2B1b KD decreases viability of a 
range of cell lines, including benign RWPE-1 cells (Supplemental Figure 3)(30,31). 
However, it is not known whether SULT2B1b modulation is capable of impacting activity of 
AR variants. Perhaps SULT2B1b KD influences transcriptional coregulators of the AR, 
causing this decrease in activity. LXR activation has also been shown to decrease AR 
activity in LNCaP cells as well as inhibit androgen-dependent proliferation in a SULT2A1-
dependent manner(28). Our data suggest that the impact of SULT2B1b on AR activity is 
independent of LXR activity, since AR activity decreases regardless of the presence of LXR 
(Figure 7D–F). Due to these findings, it is likely that other novel mechanisms of 
SULT2B1b-influence on AR activity are at play. Given that de novo androgen synthesis 
occurs within PCa cells(32), it is also possible that SULT2B1b activity is linked to synthesis 
of DHT within these cells since addition of AR ligand R1881 abrogates the growth-
inhibitory effect of SULT2B1b KD (Figure 6D).
This is the first study to demonstrate that SULT2B1b modulation alters AR activity. 
Interestingly, in preliminary RNA-sequencing studies, genes modulated by SULT2B1b KD 
significantly altered 4 out of 5 overrepresented CRPC-related pathways identified by 
Robinson, et al.(33). Regulation of c-myc, crosstalk with the PI3K/Akt pathway, and impact 
on a number of other proliferation pathways can lead to the formation of CRPC in an 
androgen-deprived environment(34–36). It may be important to determine the impact of 
SULT2B1b modulation on these pathways to better understand whether SULT2B1b aids in 
progression of PCa toward a castration non-responsive state. Since CRPC retains AR 
activity in the context of human PCa(26), it is tempting to speculate that SULT2B1b 
modulation could impact AR activity in this disease stage. Based on our data, it is clear that 
SULT2B1b is a critical regulator of PCa growth and that SULT2B1b could be the target of a 
promising anti-cancer therapeutic that would simultaneously activate LXR and inhibit AR 
activity. These data and further studies may indicate that SULT2B1b is a significant and 
novel metabolic target for treatment of human PCa at multiple stages of the disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cholesterol sulfate accumulation correlates with SULT2B1b expression in PCa cells 
and human prostate specimens
A) Analysis of human prostate cancer by IHC for SULT2B1b (left), H&E staining (middle), 
and DESI-MS detection of cholesterol sulfate at m/z 465 (right). These sections were 
derived from one representative patient out of a sampling of 8 patients. B–C) Basal 
SULT2B1b expression was determined in indicated prostate cell lines by qRT-PCR 
(normalized to 18s rRNA) (B) and western blot (C). Error bars represent the mean +/− SEM 
of 3 replicate analyses. D) DESI-MS spectra of prostate cell lines from (B–C). Cholesterol 
sulfate expression is indicated by a peak at m/z 465 (indicated in red). E–F) Stable DU145-
SULT2B1b cells were treated with or without 1 µg/mL doxycycline for induction of 
SULT2B1b cDNA expression and analyzed by DESI-MS. E) A western blot detecting 
SULT2B1b and β-actin in wildtype DU145 (Ø), DU145-SULT2B1b +Dox, and DU145-
SULT2B1b –Dox is shown. F) DESI-MS negative ion spectra in DU145-SULT2B1b +/− 
Dox cells from (E) indicate the relative abundance of cholesterol sulfate in cells by a peak at 
m/z 465.
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Figure 2. Targeted knockdown of SULT2B1b impairs growth/viability of PCa cells
A–C) Western blot of SULT2B1b protein expression in LNCaP (A), VCaP (B) and C4-2 (C) 
cells after a 72 hour incubation with non-targeting (control), or SULT2B1b siRNA. D) 
LNCaP cells were transfected with scrambled control or SULT2B1b shRNA vector. After 24 
hours, cells were split into 96-well plates and allowed to grow for 7 days before counting the 
number of colonies. *indicates p<0.05. Data represents mean +/− SEM of three independent 
experiments. E–G) Cell viability/growth curves in LNCaP (E), VCaP (F) and C4-2 (G) cells 
with treatment of control or SULT2B1b siRNA on day 0. Cell viability was measured via 
MTS assay at indicated time points. Each point represents the mean +/− SEM of 3–4 
duplicate wells from each sample and growth curves are representative of three independent 
experiments. Statistics were completed at each time point using a student’s t-test with 
Bonferroni correction. *=p-value of <0.05, **=p-value of <0.01, and ***= p-value of <0.001 
compared to control KD cells.
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Figure 3. SULT2B1b KD induces cell death in PCa cells
LNCaP and VCaP cells were transfected with control or SULT2B1b siRNA and harvested 
after 72 hours. A) Cell cycle analysis of LNCaP (left) and VCaP (right) cells. Cell samples 
were analyzed by flow cytometry after fixing and staining with propidium iodide (PI). Data 
is representative of three independent experiments. B) Caspase-3 activity in LNCaP (left) 
and VCaP (right) cells was determined by luminescence assay after control or SULT2B1b 
siRNA KD. Results indicate the mean ± SEM of three independent 
experiments.***indicates p<0.001 C) Western blots of indicated proteins after control or 
SULT2B1b siRNA transfection in LNCaP (left) and VCaP (right) cells. D) A representative 
sample of LNCaP cells after incubation with control or SULT2B1b siRNA Annexin-V and 
PI. Cells were harvested and stained before analysis by flow cytometry. E) Summary of 
replicate samples shown in (D). Data represents the %Annexin-V+/PI- cells out of the total 
population of events (excluding doublets) and is representative of three independent 
experiments performed in duplicate. ****indicates p<0.0001
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Figure 4. Cell death resulting from SULT2B1b KD persists with pan-caspase inhibition
A) Caspase-3 activity in LNCaP cells at 72 hours after transfection. Bars indicate the mean
±SEM of duplicate experiments. B) Cell viability determined via trypan blue cell counting 
in LNCaP cells at indicated time points after control or SULT2B1b siRNA KD with and 
without addition of 20µM pan-caspase inhibitor, Z-vad. C) LNCaP cells were treated with 
20µM Z-vad at the time of control or SULT2B1b siRNA transfection. After 72 hours, cells 
were harvested, incubated with Annexin-V and PI, and analyzed by flow cytometry. Bars 
represent the mean ± SEM of %Annexin-V+/PI- cells within total events collected 
(excluding doublets) from three independent experiments. D) Graph of MTS assay endpoint 
analysis in LNCaP cells after 96 hours of control or SULT2B1b siRNA KD as well as 
treatment with 20µM Z-vad and/or 10µM Necrostatin-1. Z-vad was added every 24 hours 
and Necrostatin-1 was added every 48 hours in applicable samples. Bars represent the mean 
+/− SEM of three independent experiments. Statistical analysis was conducted using two-
way ANOVA and Tukey’s post-test. Different letters indicate significant differences among 
treatments.
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Figure 5. SULT2B1b KD decreases AR expression and activity
A–B) LNCaP cells treated with control or SULT2B1b siRNA were harvested at 72 hours for 
mRNA expression by qRT-PCR (A) and protein by western blot (B) of indicated genes and 
proteins, respectively. C) A luciferase reporter construct controlled by the AR-responsive 
portion of the PSA promoter was transfected into LNCaP cells followed by transfection with 
control or SULT2B1b siRNA. Cells were harvested and lysed 48 hours after siRNA 
transfection. Firefly luciferase activity was normalized to Renilla. Relative luciferase units 
(RLU) are shown for cell conditions with or without addition of 1nM R1881 added 24 hours 
before harvest. Bars represent the mean ± SEM of three independent experiments. * 
indicates p<0.05 determined by t-test.
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Figure 6. AR ligand addition, but not AR overexpression, partially rescues cell growth in LNCaP 
with SULT2B1b KD
A) Western blot showing expression levels of indicated proteins with Control or SULT2B1b 
KD ± AR overexpression. Cells were harvested 60 hours after transfection with Control or 
SULT2B1b siRNA. B) Luciferase assay showing AR activity after 72 hours of siRNA 
transfection. C) MTS assay of LNCaP cells with or without AR overexpression followed by 
Control or SULT2B1b siRNA transfection. The time of siRNA transfection was considered 
Day 0 and relative absorbance was identified at the indicated time points. Each point 
represents the mean +/− SEM of 3 replicate wells. D) 72 hour endpoint analysis from an 
MTS assay of LNCaP cells that were transfected with control or SULT2B1b siRNA with or 
without addition of 10nM R1881 daily. Each bar represents the mean +/− SEM of 3 replicate 
wells and similar results were found in duplicate experiments. * indicates p<0.05 determined 
by two-way ANOVA.
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Figure 7. SULT2B1b regulates the AR independently of LXR
A–C) LNCaP cells were transiently transfected with a control vector (pcDNA3.1) or a 
construct containing the human SULT2B1b cDNA under the CMV promoter (hSULT2B1b 
vector), resulting in SULT2B1b overexpression. Western blot (A) or qRT-PCR (B) was 
performed 72 hours after transfection. Gene expression was normalized to 18S rRNA. Bars 
represent the mean +/− SEM of triplicate samples. C) A LXR-responsive luciferase reporter 
construct under the minimum SV40 promoter was transfected into LNCaP cells with basal 
expression (control vector) or overexpression (hSULT2B1b vector) of SULT2B1b. Firefly 
luciferase activity was normalized to Renilla. LXR activity was measured and further 
normalized to negative control luciferase reporter activity for each sample. D) LNCaP cells 
were treated with control or LXRβ siRNA and analyzed for LXR activity via luciferase 
assay after 72 hours. RLU was quantified and normalized as described in (C). T-tests were 
completed in (B–D) to determine significant differences. *=p-value of <0.05 and ****=p-
value of <0.0001 compared to control cells. E–F) Double siRNA KD of LXRβ and 
SULT2B1b was conducted. Bars represent the mean ± SEM of triplicate samples. E) 
SULT2B1b and LXRβ expression determined via qRT-PCR. Gene expression was 
normalized to 18S rRNA. *=p-value of <0.05, **=p-value of <0.01, and ***= p-value of 
<0.001 compared to control/controlx2 KD cells by One-way ANOVA. F) AR activity was 
evaluated through PSA expression by qRT-PCR. Gene expression was normalized to 18S 
rRNA. Statistical analysis was conducted using a one-way ANOVA and Tukey’s post-test. 
Different letters indicate significant differences among treatments.
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